Objective: Epicutaneous application of capsaicin causes a long-lasting analgesic effect by binding to the membrane transient receptor potential vanilloid 1 (TRPV1) on mechanoheat-sensitive C and Aδ fibres, changing axonal integrity and inhibiting neurogenic inflammatory processes. To date, no information is available regarding the cutaneous drug delivery of capsaicin following patch application. Methods: Using a Franz diffusion cell, the cutaneous concentration-time profiles 30, 60 and 90 min after application of a patch containing 8% capsaicin (640 µg/cm2) on ex vivo thin (mamma) and thick (plantar) human skin were investigated at 32°C, and additionally at 42°C for thin skin and 10°C for thick skin. An HPLC-MS method was used for the analytic detection of capsaicin. Results: The results show that already after a 30-min application of the 8% capsaicin patch, an equilibrium reservoir can be found in the stratum corneum in both thick and thin skin. Under physiological temperature conditions, a sufficient bioavailability of capsaicin in the cutaneous target compartments can be found. Raising the temperature to 42°C has no relevant impact on the concentration-time profile, while reducing the temperature to 10°C leads to a significantly lower bioavailability. Conclusion: After 30 min of application, a sufficient cutaneous bioavailability of capsaicin is reached in thick as well as thin skin. Whether shorter application times may suffice to achieve therapeutic effectiveness requires further investigation. © 2014 S. Karger AG, Basel

Keywords:
Capsaicin, Cutaneous drug delivery, Dermal patch
1.
Virus RM, Gebhart GF: Pharmacologic actions of capsaicin: apparent involvement of substance P and serotonin. Life Sci 1979;25:1273-1283.
2.
Toh CC, Lee TS, Kiang AK: The pharmacological actions of capsaicin and analogues. Br J Pharmacol Chemother 1955;10:175-182.
3.
Reyes-Escogido Mde L, Gonzalez-Mondragon EG, Vazquez-Tzompantzi E: Chemical and pharmacological aspects of capsaicin. Molecules 2011;16:1253-1270.
4.
Gunthorpe MJ, Benham CD, Randall A, et al: The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci 2002;23:183-191.
5.
Hagenacker T, Splettstoesser F, Greffrath W, et al: Capsaicin differentially modulates voltage-activated calcium channel currents in dorsal root ganglion neurones of rats. Brain Res 2005;1062:74-85.
6.
Facer P, Casula MA, Smith GD, et al: Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol 2007;7:11.
7.
Gopinath P, Wan E, Holdcroft A, et al: Increased capsaicin receptor TRPV1 in skin nerve fibres and related vanilloid receptors TRPV3 and TRPV4 in keratinocytes in human breast pain. BMC Womens Health 2005;5:2.
8.
Serra J, Campero M, Bostock H, et al: Two types of C nociceptors in human skin and their behavior in areas of capsaicin-induced secondary hyperalgesia. J Neurophysiol 2004;91:2770-2781.
9.
Forst T, Pohlmann T, Kunt T, et al: The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy. Acta Diabetol 2002;39:1-6.
10.
Inoue K, Koizumi S, Fuziwara S, et al: Functional vanilloid receptors in cultured normal human epidermal keratinocytes. Biochem Biophys Res Commun 2002;291:124-129.
11.
Stander S, Moormann C, Schumacher M, et al: Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol 2004;13:129-139.
12.
Rau KK, Jiang N, Johnson RD, et al: Heat sensitization in skin and muscle nociceptors expressing distinct combinations of TRPV1 and TRPV2 protein. J Neurophysiol 2007;97:2651-2662.
13.
Russell LC, Burchiel KJ: Neurophysiological effects of capsaicin. Brain Res 1984;320:165-176.
14.
McCusker MT, Chung KF, Roberts NM, et al: Effect of topical capsaicin on the cutaneous responses to inflammatory mediators and to antigen in man. J Allergy Clin Immunol 1989;83:1118-1124.
15.
Stephens DP, Charkoudian N, Benevento JM, et al: The influence of topical capsaicin on the local thermal control of skin blood flow in humans. Am J Physiol Regul Integr Comp Physiol 2001;281:R894-R901.
16.
Benham CD, Gunthorpe MJ, Davis JB: TRPV channels as temperature sensors. Cell Calcium 2003;33:479-487.
17.
Magerl W, Fuchs PN, Meyer RA, et al: Roles of capsaicin-insensitive nociceptors in cutaneous pain and secondary hyperalgesia. Brain 2001;124:1754-1764.
18.
Polydefkis M, Hauer P, Sheth S, et al: The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain 2004;127:1606-1615.
19.
Anand P, Bley K: Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011;107:490-502.
20.
Reilly CA, Ehlhardt WJ, Jackson DA, et al: Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol 2003;16:336-349.
21.
Fujiuchi A, Toga T: Pharmacological effect of capsaicin on rat avoidance behaviours elicited by sine-wave electrical stimulation of different frequencies by Neurometer. J Pharm Pharmacol 2008;60:467-471.
22.
Richeux F, Cascante M, Ennamany R, et al: Cytotoxicity and genotoxicity of capsaicin in human neuroblastoma cells SHSY-5Y. Arch Toxicol 1999;73:403-409.
23.
Chanda S, Bashir M, Babbar S, et al: In vitro hepatic and skin metabolism of capsaicin. Drug Metab Dispos 2008;36:670-675.
24.
Gooding SM, Canter PH, Coelho HF, et al: Systematic review of topical capsaicin in the treatment of pruritus. Int J Dermatol 2010;49:858-865.
25.
Lambert DG: Capsaicin receptor antagonists: a promising new addition to the pain clinic. Br J Anaesth 2009;102:153-155.
26.
Van der Schueren BJ, Rogiers A, Vanmolkot FH, et al: Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model. J Pharmacol Exp Ther 2008;325:248-255.
27.
Schmelz M, Schmid R, Handwerker HO, et al: Encoding of burning pain from capsaicin-treated human skin in two categories of unmyelinated nerve fibres. Brain 2000;123:560-571.
28.
Del Bianco E, Geppetti P, Zippi P, et al: The effects of repeated dermal application of capsaicin to the human skin on pain and vasodilatation induced by intradermal injection of acid and hypertonic solutions. Br J Clin Pharmacol 1996;41:1-6.
29.
Wallengren J, Chen D: Local skin lesions in the rat after subcutaneous deposition of capsaicin. Skin Pharmacol Physiol 2002;15:154-165.
30.
Fitzgerald M: Capsaicin and sensory neurones: a review. Pain 1983;15:109-130.
31.
Chaiyasit K, Khovidhunkit W, Wittayalertpanya S: Pharmacokinetic and the effect of capsaicin in Capsicum frutescens on decreasing plasma glucose level. J Med Assoc Thai 2009;92:108-113.
32.
Brand LM, Skare KL, Loomans ME, et al: Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345. Agents Actions 1990;31:329-340.
33.
Weisshaar E, Ziethen B, Gollnick H: Lack of efficacy of topical capsaicin in serotonin-induced itch. Skin Pharmacol Physiol 2000;13:1-8.
34.
Zhai H, Simion FA, Abrutyn E, Koehler AM, Maibach HI: Screening topical antipruritics: a histamine-induced itch human model. Skin Pharmacol Physiol 2002;15:213-217.
35.
Davies JW, Hainsworth AH, Guerin CJ, et al: Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-dopamine-evoked cell death in a homogeneous transient receptor potential vanilloid subtype 1 receptor population. Br J Anaesth 2010;104:596-602.
36.
Babbar S, Marier JF, Mouksassi MS, et al: Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit 2009;31:502-510.
37.
Qutenza 179 mg cutaneous patch: summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000909/WC500040453.pdf (accessed April 4, 2013).
38.
Backonja M, Wallace MS, Blonsky ER, et al: NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008;7:1106-1112.
39.
Simpson DM, Gazda S, Brown S, et al: Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage 2010;39:1053-1064.
40.
Irving GA, Backonja MM, Dunteman E, et al: A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 2011;12:99-109.
41.
Clifford DB, Simpson DM, Brown S, et al: A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr 2012;59:126-133.
42.
Webster LR, Tark M, Rauck R, et al: Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurol 2010;10:92.
43.
Kennedy WR, Vanhove GF, Lu SP, et al: A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain 2010;11:579-587.
44.
Martini C, Yassen A, Olofsen E, et al: Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza) in diabetic neuropathic pain patients: detection of distinct response groups. J Pain Res 2012;5:51-59.
45.
Jones VM, Moore KA, Peterson DM: Capsaicin 8% topical patch (Qutenza): a review of the evidence. J Pain Palliat Care Pharmacother 2011;25:32-41.
46.
Simpson DM, Estanislao L, Brown SJ, et al: An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy. J Pain Symptom Manage 2008;35:299-306.
47.
Hautkappe M, Roizen MF, Toledano A, et al: Review of the effectiveness of capsaicin for painful cutaneous disorders and neural dysfunction. Clin J Pain 1998;14:97-106.
48.
Rains C, Bryson HM: Topical capsaicin: a review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging 1995;7:317-328.
49.
Tandan R, Lewis GA, Krusinski PB, et al: Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care 1992;15:8-14.
50.
Peppin JF, Majors K, Webster LR, et al: Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain. J Pain Res 2011;4:385-392.
51.
Treede RD, Wagner T, Kern KU, et al: Mechanism- and experience-based strategies to optimize treatment response to the capsaicin 8% cutaneous patch in patients with localized neuropathic pain. Curr Med Res Opin 2013;29:527-538.
52.
Knolle E, Zadrazil M, Kovacs GG et al: Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study. Pain 2013;154:2729-2736.
53.
OECD: OECD guideline for the testing of chemicals, section 4. Test No. 428. Skin absorption: in vitro method. 2004. http://www.oecd-ilibrary.org/docserver/download/9742701e.pdf?expires=1365075065&id=id&accname=guest&checksum=17EA2B94BD8400DC17F04BCCE29BCF64 (accessed April 4, 2013).
54.
OECD: OECD guideline for the testing of chemicals, section 4. Test No. 427. Skin absorption: in vivo method. 2004. http://www.oecd-ilibrary.org/docserver/download/9742701e.pdf?expires=1365075386&id=id&accname=guest&checksum=59CF7806275A34C7AD402EC58E753FCF (accessed April 4, 2013).
55.
OECD: Guidance document for the conduct of skin absorption studies. 2004. http://search.oecd.org/officialdocuments/displaydocumentpdf/?doclanguage=en&cote=env/jm/mono(2004)2 (accessed April 4, 2013).
56.
Garces-Claver A, Gil-Ortega R, Alvarez-Fernandez A, et al: Inheritance of capsaicin and dihydrocapsaicin, determined by HPLC-ESI/MS, in an intraspecific cross of Capsicum annuum L. J Agric Food Chem 2007;55:6951-6957.
57.
Henderson DE, Slickman AM, Henderson SK: Quantitative HPLC determination of the antioxidant activity of capsaicin on the formation of lipid hydroperoxides of linoleic acid: a comparative study against BHT and melatonin. J Agric Food Chem 1999;47:2563-2570.
58.
Wolf R, Huschka C, Raith K, et al: Rapid quantification of capsaicin and dihydrocapsaicin in human skin extracts after dermal administration using HPLC-ESI-MS. J Liq Chromatogr Relat Technol 1999;22:531-539.
59.
Roberts K, Shenoy R, Anand P: A novel human volunteer pain model using contact heat evoked potentials (CHEP) following topical skin application of transient receptor potential agonists capsaicin, menthol and cinnamaldehyde. J Clin Neurosci 2011;18:926-932.
60.
de Tommaso M, Sardaro M, Pecoraro C, et al: Effects of the remote C fibres stimulation induced by capsaicin on the blink reflex in chronic migraine. Cephalalgia 2007;27:881-890.
61.
Shirakawa H, Yamaoka T, Sanpei K, et al: TRPV1 stimulation triggers apoptotic cell death of rat cortical neurons. Biochem Biophys Res Commun 2008;377:1211-1215.
62.
Ko F, Diaz M, Smith P, et al: Toxic effects of capsaicin on keratinocytes and fibroblasts. J Burn Care Rehabil 1998;19:409-413.
63.
Hermann RC, Taylor RS, Ellis CN, et al: Topical ciclosporin for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacol 1988;1:246-249.
64.
Zesch A, Schaefer H, Hoffmann W: Barrier and reservoir function of individual areas of the horny layers of human skin for locally administered drugs (in German). Arch Dermatol Forsch 1973;246:103-107.
65.
Webster LR, Malan TP, Tuchman MM, et al: A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J Pain 2010;11:972-982.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.